You are here
NucliSens® miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.02 April, 2004
bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.
NucliSens® miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.
Marcy l'Etoile, France - April 2, 2004. bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.
“These two products make up a novel platform for the generic extraction of DNA and RNA in multiple specimen types and underline our commitment to provide molecular laboratories with state-of-the-art products” says Frank Simons, Global Product Manager for Molecular Diagnostics. “Like the current NucliSens extraction products, the new platform is also based on our proprietary BOOM® technology, which is considered to be the gold standard in the field. The new system however works with magnetic silica, which is easy to manipulate using the magnetic back panel of the NucliSens miniMAG.”
NucliSens miniMAG works with a universal procedure, capable of effectively extracting both DNA and RNA. Offering a high level of flexibility, this innovative instrument makes it possible to test multiple biological specimen types (e.g. serum, plasma, blood, CSF, stools, sputum, virus cultures) and different sample volumes in the same run. Furthermore, it provides outstanding nucleic acid purity and high DNA and RNA recovery, enabling sensitive and robust downstream molecular testing applications based on different amplification technologies (e.g. NASBA®, PCR).
NucliSens miniMAG offers an easy-to-use, cost-effective and high capacity extraction solution, attractive for most molecular laboratories. In addition, the NucliSens miniMAG platform will be fully compatible with an automated platform currently under development within bioMérieux, for future upgrading of molecular laboratory strategies.